Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An exploratory study to evaluate the efficacy, safety, particularly renal function, and tolerability of three regimes of immunosuppressive therapy, in patients who have undergone liver transplantation

Next Previous
X
Search
Trial Profile

An exploratory study to evaluate the efficacy, safety, particularly renal function, and tolerability of three regimes of immunosuppressive therapy, in patients who have undergone liver transplantation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daclizumab (Primary) ; Mycophenolate mofetil (Primary) ; Mycophenolate mofetil (Primary) ; Tacrolimus (Primary) ; Corticosteroids
  • Indications Liver transplant rejection
  • Focus Adverse reactions
  • Acronyms Elite-ReSpECT; ReSpECT
  • Sponsors Roche

    • Most Recent Events

    • 23 Feb 2010 Additional trial location (Austria) added as reported by Roche record.
    • 09 Jan 2008 Status changed from in progress to completed.
    • 01 Oct 2007 Six- and 12-month data presented at ESOT 2007.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top